Classes
DEA Class; Rx
Common Brand Names; Apresoline
- Vasodilators
Description
Indications
Indicated for the treatment of hypertension.
Contraindications
Hypersensitivity to hydralazine
Coronary artery disease
Mitral valve rheumatic heart disease
Adverse Effects
- Hypotension
- Palpitations
- Conjunctivitis
- Tachycardia
- Headache
- Peripheral edema
- Vascular collapse
- Peripheral neuropathy
- Anorexia
- Diarrhea
- Nausea
- Vomiting
- Psychotic reaction
- Agranulocytosis
- Leukopenia
- Hepatotoxicity
- Chest pain
- Dyspnea
- Nasal congestion
- Paralytic ileus
- Dysurea
- Thrombocytopenia
- Peripheral neuritis
- Rheumatoid arthritis
- Agranulocytosis
- Arthralgia
- SLE syndrome
Warnings
May induce SLE-type syndrome (usually at >200 mg/day); instruct patients to report joint/chest pain or fever; discontinue therapy unless benefits outweigh risks; steroid therapy may be necessary long-term
Use caution in CVA, severe renal impairment, volume depletion, preexisting hypotension, concurrency with other hypotensive agents, CAD (potential contraindication)
Use caution in mitral valvular disease; may increase pulmonary artery pressure
Discontinue slowly to avoid rapid rise in blood pressure
Use with caution in patients with pulmonary hypertension; may cause hypotension
Increases fluid and sodium retention; may require treatment or increase in diutretic dose
Peripheral neuritis, including numbness, paresthesia, and tingling, reported; treat symptoms with pyridoxine
Blood dyscarsias, including reduction in red blod cell count, agranulocytosis, leukopenia, reported with therapy; discontinue therapy if any of the hematologic effects occur
Pregnancy and Lactation
Pregnancy category: C
Lactation: Excreted in breast milk; use caution
Maximum Dosage
300 mg/day PO for hypertension. Higher doses have been used to treat patients with heart failure; however, doses greater than 200—300 mg/day PO are associated with a higher risk of drug-induced systemic lupus erythematosus. Titrate IV and IM dosage as needed for blood pressure control.
300 mg/day PO for hypertension. Higher doses have been used to treat patients with heart failure; however, doses greater than 200—300 mg/day PO are associated with a higher risk of drug-induced systemic lupus erythematosus. Titrate IV and IM dosage as needed for blood pressure control.
Safety and efficacy not established; however, doses up to 7.5 mg/kg/day PO or 200 mg/day PO, whichever is less, or 3.5 mg/kg/day IV or IM have been used.
Safety and efficacy not established; however, doses up to 7.5 mg/kg/day PO or 200 mg/day PO, whichever is less, or 3.5 mg/kg/day IV or IM have been used.
Safety and efficacy not established; however, doses up to 7.5 mg/kg/day PO or 3.5 mg/kg/day IV or IM have been used.
Safety and efficacy not established; however, doses up to 7.5 mg/kg/day PO or 0.6 mg/kg/dose IV have been used.
How supplied
Hydralazine hydrochloride
injectable solution
- 20mg/mL
tablets
- 10mg
- 25mg
- 50mg
- 100mg